DIMETHYL ITACONATE
하는 일
- 산소와 반응해 제품이 상하는 것을 늦춤
- 위 어디에도 속하지 않는 피부 컨디셔닝
- 외부 자극으로부터 피부를 보호함
- 모발을 부드럽게 함
정의
이 원료는 다음의 구조를 갖는 유기화합물이다.
출처: 식약처 화장품 원료성분
미국 FDA 물질 등록 · UNII 11JIB0YI93 · 등록명 DIMETHYL ITACONATE · 단일 화학물질
다른 언어 정의 1개
Dimethyl Itaconate is the organic compound that conforms to the formula
화장품에서 하는 역할
산소와 반응해 제품이 상하는 것을 늦춤ANTIOXIDANT위 어디에도 속하지 않는 피부 컨디셔닝SKIN CONDITIONING - MISCELLANEOUS외부 자극으로부터 피부를 보호함SKIN PROTECTING모발을 부드럽게 함HAIR CONDITIONING
안전·규제 요약
국내 유독물 GHS 분류 없음 · 기존화학물질
자세한 자료 — 표시명·식별번호·물성·시험 기록·문헌
별칭·식별 정보
DIMETHYL ITACONATEINCI다이메틸이타코네이트식약처 표준명
- CAS No.화학물질 등록번호
- 617-52-7
- EC No.EU 화학물질 목록번호
- 210-519-6
- DTXSID미국 환경청(EPA) 화학물질 번호
- DTXSID80210701
- DTXCID미국 환경청(EPA) 화합물 번호
- DTXCID70133192
- IUPAC
- Dimethyl 2-methylidenebutanedioate
- 분자식
- C7H10O4
- 분자량
- 158.153 g/mol
측정된 물성
- 성상
- 고체, 일부 액체
- 녹는점/어는점
- 38 ℃(EXP)
- 초기 끓는점과 끓는점 범위
- 208 ℃(EXP)
- 인화점
- 100 ℃(c.c)
- 용해도
- 14030 ㎎/ℓ (추정값, 약수용성)
- 비중
- 1.1241 ( at 18℃)
- n-옥탄올/물분배계수 (Kow)
- 0.820 (추정값)
- 분자량
- 158.152
물질 자체를 측정한 값입니다. 안전보건공단 자료는 MSDS 작성·검토 참고용이며, 원료 상품의 규격은 아닙니다.
자극·감작 시험 기록
피부 시험 5건 · 눈 시험 4건이 기록되어 있습니다.
자극 높음으로 분류3건중간으로 분류1건
시험 결론이 대체로 일치합니다(75%). 원료 자체를 시험한 기록이고, 완제품에 든 농도에서의 자극성과는 다릅니다.
시험 9건 전부 보기
- Severe Irritation
skin corrosion: in vitro / ex vivo · Screening · OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method) adopted 22 July 2010 according to EU Method B.46 (In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test) according to - Corrosive
skin corrosion: in vitro / ex vivo · Screening · EU Method B.46 (In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test) Official Journal of the European Union No. L142; Amended by EC No. 640/2012 OJ No. L193, 20 July 2012 ( (EpiSkin model)) according to OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method) adopted 26 July 2013 (EpiSkin model) according to - SkinSens1
Skin Sensitization · QSAR Predicted - High Frequency of Sensitization
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) as at 2002 according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay) as at 2008 according to EPA OPPTS 870.2600 (Skin Sensitisation) as at 2003 - Low to Moderate Frequency of Sensitization
skin sensitisation: in vivo (LLNA) · Screening · according to OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay) according to EU Method B.42 (Skin Sensitisation: Local Lymph Node Assay) - Studies Indicate No Significant Irritation
eye irritation: in vivo · Screening · other guideline: FAMIC according to OECD Guideline 405 (Acute Eye Irritation / Corrosion) according to EU Method B.5 (Acute Toxicity: Eye Irritation / Corrosion) according to EPA OPPTS 870.2400 (Acute Eye Irritation) according to - Corrosive or Irritation Persists for > 21 days
eye irritation: in vitro / ex vivo · Screening · OECD Guideline 437 (Bovine Corneal Opacity and Permeability Test Method for Identifying Ocular Corrosives and Severe Irritants) [before 26 July 2013] according to EU method B.47 (Bovine corneal opacity and permeability test method for identifying ocular corrosives and severe irritants) according to - Corrosive or Irritation Persists for > 21 days
eye irritation: in vitro / ex vivo · Screening · other guideline: OECD Guideline no. 437: "Bovine corneal opacity and permeability (BCOP) test method for identifying ocular corrosives and severe irritants" (adopted September 07, 2009) according to - Moderate or Mild Irritation
eye irritation: in vitro / ex vivo · Screening · OECD Guideline 437 (Bovine Corneal Opacity and Permeability Test Method for Identifying Ocular Corrosives and Severe Irritants) [before 26 July 2013] according to EU method B.47 (Bovine corneal opacity and permeability test method for identifying ocular corrosives and severe irritants) according to
출처: 미국 EPA CompTox
관련 문헌
- Dimethyl itaconate suppresses dendritic cell and CD8+ T cell responses to halt vitiligo · 2025
- ISG15 deficiency features a complex cellular phenotype that responds to treatment with itaconate and derivatives · 2022
- Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata · 2022
- Dimethyl itaconate, an itaconate derivative, exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis · 2020
- Dimethyl itaconate, an itaconate derivative, exhibits immunomodulatory effects on neuroinflammation in experimental autoimmune encephalomyelitis · 2020